Hostname: page-component-586b7cd67f-vdxz6 Total loading time: 0 Render date: 2024-12-01T02:30:43.826Z Has data issue: false hasContentIssue false
  • English
  • Français

Cost-effectiveness analysis of lemborexant for treating insomnia in Japan: A model-based projection, incorporating the risk of falls, motor vehicle collisions, and workplace accidents – CORRIGENDUM

Published online by Cambridge University Press:  30 June 2022

Shunya Ikeda Open the ORCID record for Shunya Ikeda [Opens in a new window] ,
Mie Kasai Azuma ,
Kenichi Fujimoto ,
Hidetoshi Shibahara ,
Sachie Inoue ,
Margaret Moline ,
Mika Ishii  and
Kazuo Mishima
Shunya Ikeda
Affiliation:
Department of Public Health, School of Medicine, International University of Health and Welfare, Narita, Japan
Mie Kasai Azuma
Affiliation:
Eisai Co., Ltd., Tokyo, Japan
Kenichi Fujimoto
Affiliation:
Eisai Co., Ltd., Tokyo, Japan
Hidetoshi Shibahara
Affiliation:
CRECON Medical Assessment Inc., Tokyo, Japan Graduate School of Health and Welfare, International University of Health and Welfare, Tokyo, Japan
Sachie Inoue
Affiliation:
CRECON Medical Assessment Inc., Tokyo, Japan
Margaret Moline
Affiliation:
Eisai Inc., Woodcliff Lake, NJ, USA
Mika Ishii
Affiliation:
Eisai Co., Ltd., Tokyo, Japan
Kazuo Mishima
Affiliation:
Department of Neuropsychiatry, Akita University Graduate School of Medicine, Akita, Japan
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.
Type
Corrigendum
Information
Psychological Medicine , Volume 52 , Issue 13 , October 2022 , pp. 2847
Check for updates
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
Copyright © The Author(s), 2022. Published by Cambridge University Press

This article was published in Psychological Medicine with the reference ‘Ikeda, S., Azuma, M., Fujimoto, K., Shibahara, H., Inoue, S., Moline, M., & Ishii, M. (Reference Ikeda, Azuma, Fujimoto, Shibahara, Inoue, Moline and Mishima2020). PMH8 EQ-5D Analysis in Patients with Insomnia: Change of Quality of Life in Lemborexant Phase 3 Trial Sunrise 1. Value in Health, 23. doi:10.1016/j.jval.2020.08.1086’ missing. The online version of this article has been updated to include this reference.

The authors apologise for this error.

References

Ikeda, S., Azuma, M., Fujimoto, K., Shibahara, H., Inoue, S., Moline, M., . . . Mishima, K. (2022). Cost-effectiveness analysis of lemborexant for treating insomnia in Japan: A model-based projection, incorporating the risk of falls, motor vehicle collisions, and workplace accidents. Psychological Medicine, 1–13. doi:10.1017/S0033291722000356Google ScholarPubMed